Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDK4/6 Inhibitors + Endocrine Therapy in Neoadjuvant HR+/HER2- Breast Cancer
NCT07130643Phase 2Active, not recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib, palbociclib, abemaciclib, ribociclib in breast cancer. Started Dec 2024; status: active, not recruiting.
02
Drugs
dalpiciclibpalbociclibabemaciclibribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07130643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07130643.